| Trial ID: | L1991 |
| Source ID: | NCT04203927
|
| Associated Drug: |
Empagliflozin 25 Mg
|
| Title: |
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
|
| Acronym: |
EJB051
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes|Insulin Sensitivity
|
| Interventions: |
DRUG: Empagliflozin 25 MG
|
| Outcome Measures: |
Primary: Myocardial microvascular perfusion, Vascular measure of myocardial perfusion, Between baseline and 12 weeks treatment | Secondary: Flow Mediated Dilation (FMD) Vascular measure of conduit artery stiffness Change in Flow Mediated Dilation (FMD) between baseline and after 2 hour insulin clamp Vascular measure of conduit artery stiffness Flow Mediated Dilation ( FMD), Vascular measure of conduit artery stiffness, Between baseline and 12 weeks of treatment.|Augmentation Index ( AI), Measurement of central artery stiffness, Between baseline and 12 weeks of treatment.|Pulse Wave Velocity ( PWV), Measurement of central artery stiffness, Between baseline and 12 weeks of treatment
|
| Sponsor/Collaborators: |
Sponsor: University of Virginia | Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2020-02-01
|
| Completion Date: |
2023-11-30
|
| Results First Posted: |
|
| Last Update Posted: |
2022-02-10
|
| Locations: |
University of Virginia, Charlottesville, Virginia, 22906, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04203927
|
